Harmony Biosciences Holdings
Harmony Biosciences Holdings Inc is an American commercial-stage pharmaceutical enterprise specializing in the discovery, acquisition, development, and commercialization of innovative therapies for patients living with rare neurological diseases and central nervous system (CNS) disorders, prominently featuring Wakix (pitolisant) prescribed for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company conducts advanced clinical research evaluating neurodevelopmental and psychiatric therapeutic candidates. Its core business operations encompass pharmaceutical commercialization, clinical-stage drug development, rare disease neurology research, and medical affairs management. Revenue is derived primarily from direct commercial product sales of Wakix across the United States. Harmony Biosciences Holdings holds a leading market position in rare central nervous system therapeutics and narcolepsy treatment. The company is headquartered in Plymouth Meeting, Pennsylvania, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker HRMY.
6 of the funds FundTelligence covers report a position in Harmony Biosciences Holdings.
- Legal name
- Harmony Biosciences Holdings Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
Funds holding Harmony Biosciences Holdings
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.29 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.17 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)